Temaz and Neurotoxicity - a phase IV clinical study of FDA data

Summary:

Neurotoxicity is reported as a side effect among people who take Temaz (temazepam), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Metoclopramide, and have Attention deficit hyperactivity disorder.

The phase IV clinical study analyzes which people have Neurotoxicity when taking Temaz. It is created by eHealthMe based on reports of 40,916 people who have side effects when taking Temaz from the FDA, and is updated regularly.

What is Temaz?

Temaz has active ingredients of temazepam. It is often used in insomnia. eHealthMe is studying from 42,293 Temaz users. Check the latest studies of Temaz.

What is Neurotoxicity?

Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system) is found to be associated with 677 drugs and 852 conditions by eHealthMe. Check the latest studies of Neurotoxicity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 20, 2026

40,916 people reported to have side effects when taking Temaz.
Among them, 34 people (0.08%) have Neurotoxicity.

Among these 34 people:

How long have people been on Temaz when they have Neurotoxicity? *

What is the gender of people who have Neurotoxicity when taking Temaz? *

female: 60.61 %
male: 39.39 %

What is the age of people who have Neurotoxicity when taking Temaz? *

What are other drugs people take besides Temaz? *

Acetylsalicylic Acid: 6 people, 17.65%
Ondansetron: 6 people, 17.65%
Amlodipine: 6 people, 17.65%
Metoclopramide: 6 people, 17.65%
Cytarabine: 5 people, 14.71%
Tamsulosin: 4 people, 11.76%
Paracetamol: 4 people, 11.76%
Piperacillin And Tazobactam: 3 people, 8.82%
Bactrim: 3 people, 8.82%
Augmentin: 3 people, 8.82%

What are other side effects people have besides Neurotoxicity? *

Nervousness: 10 people, 29.41%
Cytokine Release Syndrome (immediate complication occurring with the use of anti-t cell antibody infusions): 9 people, 26.47%
Nausea (feeling of having an urge to vomit): 7 people, 20.59%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 6 people, 17.65%
Fever: 5 people, 14.71%
Hypotension (abnormally low blood pressure): 5 people, 14.71%
Hypophagia (reduced food intake): 5 people, 14.71%
Headache (pain in head): 5 people, 14.71%
Oedema Peripheral (superficial swelling): 5 people, 14.71%
Upper Respiratory Tract Infection: 5 people, 14.71%

What are the existing conditions these people have? *

Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 10 people, 29.41%
Constipation: 9 people, 26.47%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 5 people, 14.71%
Sleep Disorder: 5 people, 14.71%
Bone Marrow Conditioning Regimen: 5 people, 14.71%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 5 people, 14.71%
Asthma: 4 people, 11.76%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 4 people, 11.76%
Fever: 4 people, 11.76%
Hypokalemia (low potassium): 4 people, 11.76%

* Approximation only. Some reports may have incomplete information.

Do you take Temaz and have Neurotoxicity?

- Check whether Neurotoxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Temaz:

Temaz (42,293 reports)

Neurotoxicity treatments and more:

Neurotoxicity (16,742 reports)

Browse all side effects of Temaz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neurotoxicity:

Neurotoxicity (677 drugs)

Browse all the conditions that are associated with Neurotoxicity:

Neurotoxicity (852 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on temazepam (the active ingredients of Temaz) and Temaz (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.